USP10 and familial pancreatic carcinoma: Our study also evaluated the therapeutic potential of targeting N1DARP using a modified stapled peptide derived from N1DARP, SAH-mAH2-5, which perturbs the USP10–N1ICD interaction and suppresses tumor growth in Notch1-activated pancreatic cancer, thus providing insights into how the N1DARP–N1ICD interaction could be targeted for the development of precise and individualized pancreatic cancer therapy.